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Purpose: Tibial osteotomy is a treatment for younger and/or
physically active patients suffering from uni-compartmental knee
osteoarthritis. The treatment intends to delay the disease pro-
gression and to stop the pain by realigning the tibia.
The aim of this study is to analyse cartilage changes in the knee
joint after High Tibial Osteotomy (HTO).
Methods: Consecutive subjects with osteoarthritis (OA) of the
knee who were placed on a waiting list for HTO surgery were
invited to take part in the MRI outcome study. Subjects were
examined before the surgery and during their first follow-up visit
(7±1 months). Further follow-up is planned for 12 and 24 months.
Primary outcome was tibiofemoral cartilage morphology mea-
sured by means of a 3 Tesla MRI scanner (Magnetom Trio,
Siemens AG, Erlangen, Germany). A previously validated fat-
suppressed gradient echo sequence with an in plane resolution
of 0.312x0.312mm and a slice thickness of 1.5 mm (repetition
time 31ms, echo time 10 ms, flip angle 20) was used. The sagittal
MRI’s were segmented by one blinded assessor using Chondro-
metrics software (Ainring, Germany). Three-dimensional mor-
phology of the tibial and femoral cartilage (mean and maximum
thickness, volume, and denuded surface area) was calculated.
The static alignment of the knee was determined from standing
full limb radiographs. The mechanical axis represents the angle
formed between an axis from the center of the femoral head to
the centre of the knee and an axis from the centre of the knee
to the centre of the ankle. The Western Ontario and McMaster
Universities Osteoarthritis Index (WOMAC) was used to assess
the effect of the treatment on the symptoms of OA.
A Wilcoxon Paired-Samples Test was used to assess statistical
significance of the differences between baseline and follow up
measurement in the patients. A significance level of 0.05 was
chosen unless otherwise indicated.
Results: A total of 12 subjects were included in the study. Three
female and 8 males with a mean (SD) age of 52 (4.5) years and a
Body Mass Index of 30 (4.4) kg/m2 were measured at baseline.
Baseline WOMAC score was 71.3 (17.1). Eight subjects had
their first follow-up MRI. One subject was lost for follow-up and 3
subjects haven’t reached their first follow-up appointment. Due to
imaging artefact the MRI of one subject couldn’t be segmented.
None of the morphological parameters showed a significant
change in any of the joint compartments (Table 1). We observed
a decrease in the medial cartilage volume (medial tibia and
P367 – Table 1. Pre- and Post-injection pain in Painful TKAs after IA-BoNT/A
Patient Daytime Pain on (0-10) NRS Nighttime Pain on (0-10) NRS Onset of Pain Relief
Pre-injection Post-injection % Improvement Pre-injection Post-injection % Improvement
Pt. 1: 73 M-R*‡ 5 3.5 30% 5 1 80% 7 days
Pt. 1: 73 M-L 6 3.5 42% 10 1 90% 7 days
Pt. 2: 56 F-R 5 2 60% 5 2 60% 7 days
Pt. 3: 81 M-R‡ 8 7.5 6% 2.5 2 20% No relief
Pt. 4: 65 M-R 7.5 3 60% 3 2 33% 11 days
Pt. 5: 56 M-L 7 1 86% 0 0 N/A 6 days
*Patient 1 had bilateral knee injection; ‡Patients who received the second injection; M, male; F, female; R, right; L, left; NRS, Numeric rating scale.
Table 1. Knee Cartilage Mean Thickness at Baseline and 6 Month Post HTO
Compartment Cartilage Thickness (mm)
Baseline Follow-up
Medial Tibia 1.58 ± 0.20 1.47 ± 0.21
Medial Femur 1.67 ± 0.41 1.61 ± 0.46
Lateral Tibia 2.34 ± 0.28 2.26 ± 0.16
Lateral Femur 2.32 ± 0.51 2.29 ± 0.43
femur) in six out of the seven patients. Symptoms were however
significantly improved 7 months after surgery (p<0.05).
Conclusions: We could not detect any regeneration of articular
cartilage within 7 months post surgery. To the contrary a trend to
a decrease in cartilage thickness could be detected in some joint
surfaces. The cause of this is not immediately apparent. It may
be explained in part by early post surgical immobilisation and
changes in weight bearing. Longer followup and a larger study
group are planned and may help clarify these early findings.
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Purpose: The painful TKA without clear etiology can be a difficult
management problem. We report data on off-label use of IA-
BoNT/A for refractory painful TKAs.
Methods: A case-series of five patients with six refractory painful
TKAs with pain >12-months received 100-units of IA-BoNT/A in
the painful joint followed by a re-injection of 200-units 8-12 weeks
later, if there was no relief with the initial injection. All conser-
vative therapeutic options including oral analgesics and anti-
inflammatory medications had been exhausted in these patients.
Infection, prosthetic loosening, and other surgically correctable
causes of pain were ruled out. Data were collected prospectively
under the purview of a Quality Assurance/Quality Improvement
initiative.
Pre- and post-injection data were collected prospectively: pain
severity on a 0-10 numeric rating scale (NRS), onset and dura-
tion of pain relief, patients’ global assessment of change (very
much improved, much improved, minimally improved, no change,
minimally worse, much worse, very much worse) and adverse
effects. Pain severity reduction of ≥ 30% (or 2-points on 0-10
scale) and ≥ 50% have been adjudicated as clinically meaningful
in patients in meta-analysis of pain trials (correlating with "much
improved" and "very much improved" categories respectively).
Results: Five patients had six painful TKAs injected (bilateral
TKA in one patient). Five of the six injected TKAs (80%) had
pain relief (Table 1). 5/6 painful TKAs had clinically significant
relief in Daytime pain (≥30% reduction) and 3/6 TKAs had ex-
cellent pain relief (≥50% reduction). Night time pain reduction
was significant in 4/5 and excelent in 3/5 TKAs (pain level was
0 in one patient at baseline). 5/6 painful TKAs had "much im-
provement" on patient global assessment. Pain relief started
6-11 days after the injection and lasted from 3 to 26 weeks
